Duodenal Jejunal Bypass Liner (DJBL) for treatment of type 2 diabetes and obesity: the risk benefit ratio from the worldwide EndoBarrier (EB) registry in 871 patients

被引：0
|
作者：
Laubner, K. [1 ]
Seufert, J. [1 ]
Aberle, J. [2 ]
Frydenberg, H. [3 ]
Munro, L. [3 ]
Fishman, S. [4 ]
Cohen, R. [5 ]
Holtmann, G. [6 ]
de Jonge, C. [7 ]
Greve, J. [7 ]
Kow, L. [8 ]
Bessell, J. [9 ]
Sourij, H. [10 ]
Benes, M.
Ryder, R. E. J. [11 ]
机构：
[1] Freiburg Univ, Freiburg, Germany
[2] Hamburg Univ, Hamburg, Germany
[3] Epworth Med Fdn, Richmond, Australia
[4] Sourasky Med, Tel Aviv, Israel
[5] Oswaldo Cruz Hosp, Sao Paulo, Brazil
[6] Princess Alexandra Hosp, Woolloongabba, Qld, Australia
[7] MUMC, Maastricht, Netherlands
[8] ABC, Adelaide, SA, Australia
[9] AOS, Adelaide, SA, Australia
[10] Med Univ, Graz, Austria
[11] City Hosp, Birmingham, W Midlands, England
来源：
DIABETOLOGIA | 2019年 / 62卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
803
引用
收藏
页码：S390 / S390
页数：1
相关论文
共 50 条
  • [21] ENDOBARRIER®, A DUODENAL-JEJUNAL BYPASS LINER DEVICE, ALTERS THE GLOBAL METABOLIC AND THE GUT BACTERIAL PROFILES OF PATIENTS WITH OBESITY AND DIABETES
    Ruban, Aruchuna
    Aldubaikhi, Ghadah
    Johnson, Nicholas A.
    Glaysher, Michael A.
    Chhina, Navpreet
    Byrne, James
    Marchesi, Julian
    Teare, Julian P.
    Goldstone, Anthony P.
    Miras, Alexander
    Li, Jia V.
    GASTROENTEROLOGY, 2023, 164 (06) : S1457 - S1457
  • [22] Duodenal-jejunal bypass liner for the treatment of type 2 diabetes and obesity: 3-year outcomes in the First National Health Service (NHS) EndoBarrier Service
    Ryder, Robert E. J.
    Yadagiri, Mahi
    Burbridge, Wyn
    Irwin, Susan P.
    Gandhi, Hardeep
    Bashir, Tahira
    Allden, Rachael A.
    Wyres, Melanie
    Cull, Melissa
    Bleasdale, John P.
    Fogden, Edward N.
    Anderson, Mark R.
    Sen Gupta, Piya
    DIABETIC MEDICINE, 2022, 39 (07)
  • [23] Endoscopic Duodenal-Jejunal Bypass Liner Treatment for Type 2 Diabetes and Obesity: Glycemic and Cardiovascular Disease Risk Factor Improvements in 1,022 Patients Treated Worldwide
    Ryder, Robert E. J.
    Laubner, Katharina
    Benes, Marek
    Haluzik, Martin
    Munro, Lynne
    Frydenberg, Harry
    Teare, Julian P.
    Ruban, Aruchuna
    Fishman, Sigal
    Santo, Erwin
    Stengel, Rainer
    De Jonge, Charlotte
    Greve, Jan W.
    Cohen, Ricardo V.
    Aboud, Cristina M.
    Holtmann, Gerald J.
    Rich, Graeme
    McMaster, Jess J.
    Battelino, Tadej
    Kotnik, Primoz
    Byrne, James P.
    Mason, John C.
    Bessell, Justin
    Bascomb, Jeanine
    Kow, Lillian
    Collins, Janes
    Chisholm, Jacob
    Pferschy, Peter N.
    Sourij, Harald
    Cull, Melissa L.
    Wyres, Melanie C.
    Drummond, Russell
    McGowan, Barbara
    Amiel, Stephanie A.
    Yadagiri, Mahi
    Sen Gupta, Piya
    Aberle, Jens
    Seufert, Jochen
    DIABETES CARE, 2023, 46 (04) : E89 - E91
  • [24] Effect of Duodenal-Jejunal Bypass Liner on Cardiovascular Risk in Patients with Type 2 Diabetes and Metabolic Syndrome
    Laubner, Katharina
    Roehlen, Natascha
    Bettinger, Dominik
    Hilger, Hanna
    Koenig, Carolin
    Krebs, Andreas
    Seufert, Jochen
    DIABETES, 2019, 68
  • [25] Six month follow-up results from a registry observing Duodenal-Jejunal Bypass Liner treatment outcomes in subjects with type 2 diabetes and/or obesity
    Koehestanie, P.
    Betzel, B.
    Janssen, I.
    Berends, F.
    de Boer, H.
    Escalona, A.
    Araya, D. T.
    Frydenburg, H.
    Fogarty, K.
    DIABETOLOGIA, 2013, 56 : S167 - S167
  • [26] Duodenal-Jejunal Bypass Liner (DJBL) Improves Cardiovascular Risk Biomarkers and Predicted 4-Year Risk of Major CV Events in Patients with Type 2 Diabetes and Metabolic Syndrome
    Roehlen, Natascha
    Laubner, Katharina
    Bettinger, Dominik
    Schwacha, Henning
    Hilger, Hanna
    Koenig, Carolin
    Grueninger, Dirk
    Krebs, Andreas
    Seufert, Jochen
    OBESITY SURGERY, 2020, 30 (04) : 1200 - 1210
  • [27] Duodenal-Jejunal Bypass Liner (DJBL) Improves Cardiovascular Risk Biomarkers and Predicted 4-Year Risk of Major CV Events in Patients with Type 2 Diabetes and Metabolic Syndrome
    Natascha Roehlen
    Katharina Laubner
    Dominik Bettinger
    Henning Schwacha
    Hanna Hilger
    Carolin Koenig
    Dirk Grueninger
    Andreas Krebs
    Jochen Seufert
    Obesity Surgery, 2020, 30 : 1200 - 1210
  • [28] ENDOSCOPICALLY DELIVERED DUODENAL-JEJUNAL BYPASS LINER TO TREAT TYPE 2 DIABETES IN OBESE PATIENTS
    Curcio, G.
    Casu, A.
    Traina, M.
    Colanino, M. Ziino
    Tuzzolino, F.
    Vizzini, G.
    Gridelli, B.
    DIGESTIVE AND LIVER DISEASE, 2014, 46 : S143 - S143
  • [29] Improvement of Type 2 Diabetes after Implantation of a Duodenal-Jejunal Bypass Liner in Obese Patients
    Betzel, B.
    Koehestanie, P.
    Dogan, K.
    Janssen, I.
    Wahab, P.
    Berends, F.
    de Boer, H.
    OBESITY SURGERY, 2013, 23 (08) : 1179 - 1180
  • [30] The Effect of 6 and 12 months Duodenal-Jejunal Bypass Liner Treatment on Obesity and Type 2 Diabetes: a Crossover Cohort Study
    Selwyn van Rijn
    Bark Betzel
    Charlotte de Jonge
    David P. J. van Dijk
    Ignace M. Janssen
    Frits J. Berends
    Nicole D. Bouvy
    Jan Willem M. Greve
    Obesity Surgery, 2018, 28 : 1255 - 1262
12345